Inscripta develops the Onyx digital genome engineering platform, a benchtop system combining an instrument, consumables, software and assays to enable scalable, automated CRISPR-based workflows and massively parallel, trackable single-cell edits. The company announced the first commercial shipment of Onyx to customers including the GeneMill at the University of Liverpool and cites customers such as Sestina Bio. Onyx is designed to accelerate the four steps of synthetic biology—design, generate, test, and learn—via InscriptaDesigner, Onyx Genome Engineering Kits, genotyping assays, and InscriptaResolver software. Inscripta highlights an IP portfolio of nearly 100 issued U.S. patents and frames the platform as enabling faster genome engineering cycles with fewer resources. The company is headquartered in Boulder, Colorado, with offices in San Diego and Pleasanton, California, and Copenhagen, Denmark. Inscripta closed a $150 million Series E financing to support commercial scaling and product deployment. Inscripta develops the Onyx Digital Genome Engineering platform, a fully automated benchtop instrument for genome-scale engineering. The platform comprises an instrument, consumables, software, and assays and enables creation of libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow. Inscripta says the platform overcomes limitations of existing CRISPR-based gene editing and enables massively parallel, trackable editing of single cells at unprecedented scale. The company plans to use new funding to accelerate applications expansion and commercialization of Onyx to meet anticipated high demand. Financially, Inscripta raised $125 million in a Series D, bringing total capital raised to $259.5 million. The company is headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego, and is backed by investors including Venrock, Foresite, Paladin Capital Group, Mérieux Développement, NanoDimension, MLS Capital, JS Capital Management, and Oak HC/FT. Inscripta develops a full suite of gene editing tools—software, instruments, reagents—and a family of CRISPR enzymes (MADzymes) intended to increase the speed and efficiency of multiplexed, single-cell gene editing. Its product portfolio includes the proprietary MAD7 enzyme, which the company has offered to commercial and academic researchers with no up-front licensing fees or reach-through royalties. Inscripta says these tools remove barriers to single-cell engineering and aim to enable advances to "feed, fuel, and heal humanity." The company expanded its Series C financing to support commercialization and market introduction of its solutions. Inscripta increased its Series C by $20M to a total of $105.5M, adding to an $85.5M financing announced in 2018. The company is led by CEO Kevin Ness and board chairman John Stuelpnagel and is headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego. Inscripta develops tools for forward cell engineering, including a family of CRISPR enzymes called MADzymes, custom nucleases for researchers and commercial partners, and integrated instruments, reagents and software. Its products are designed to increase the speed and efficiency of multiplexed, precision gene editing. The company is led by CEO Kevin Ness and is based in Boulder, CO and Pleasanton, CA. Inscripta completed a $55.5M Series C financing and plans to use the proceeds to expand research capabilities and strengthen its internal team of research experts. No operating metrics were disclosed in the article.

Total raised

$351M

Funding rounds

4

Latest round

Series E

Latest activity

Apr 2021